Entacapone

證據等級: L5

預測適應症: 10 個

Entacapone: From Parkinson's Disease to Lewy Body Dementia

One-Sentence Summary

Entacapone (DB00494) is a COMT (catechol-O-methyltransferase) inhibitor, originally used as an adjunct to levodopa/carbidopa therapy for Parkinson's disease motor fluctuations. This evidence pack is a multi-indication screen: TxGNN surfaced 10 candidate new indications (all >99% prediction score), but only 2 of the 10 have any supporting real-world evidence — Lewy Body Dementia (1 clinical trial, 3 publications) and Progressive Supranuclear Palsy-Corticobasal Syndrome (1 clinical trial). The remaining 8 candidates are pure model predictions (L5, no clinical trials or literature at all). Given a Blocking-severity data gap on safety labeling and the absence of any interventional trial actually testing entacapone in a new indication, the overall recommendation is Hold.

Quick Overview

Item	Content
Original Indication	Parkinson's disease, adjunct to levodopa/carbidopa (inferred from repurposing rationale narrative; formal MOA/indication fields are data gaps — see below)
Predicted New Indication (highest-evidence candidate)	Lewy body dementia
TxGNN Prediction Score	99.25% (rank 7 of screened candidates; top-ranked candidate overall, PLA2G6-associated neurodegeneration, scored 99.76% but has zero supporting evidence)
Evidence Level	L4 (preclinical/mechanistic + non-interventional trial only)
Finland Market Status	✗ Not Marketed (未上市)
Number of Authorizations	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Detailed mechanism-of-action data was not returned from the structured DrugBank query for this pack (flagged as data gap DG002). However, the repurposing rationale fields embedded in this evidence pack consistently describe entacapone by its established pharmacology: a peripheral COMT inhibitor that blocks the O-methylation of levodopa, thereby prolonging levodopa's plasma half-life and increasing central dopamine availability. It is approved worldwide (though not currently marketed in Finland per this pack) as an add-on to levodopa/carbidopa for Parkinson's disease patients experiencing "wearing-off" motor fluctuations.

Lewy body dementia (LBD) shares meaningful pathophysiology with Parkinson's disease: both are alpha-synucleinopathies with substantial nigrostriatal dopaminergic neuron loss, and LBD patients frequently exhibit parkinsonian motor symptoms that are treated off-label with levodopa-based regimens. Extending COMT inhibition to LBD is mechanistically plausible as a way to enhance dopaminergic therapy efficacy in this population. One in-vitro study in the evidence base (PMID 23913715) additionally suggests some antiparkinsonian agents may influence alpha-synuclein oligomer formation, offering a secondary, exploratory molecular rationale — though this evidence is indirect (in vitro only) and does not establish clinical efficacy.

A second, weaker candidate — Progressive Supranuclear Palsy–Corticobasal Syndrome (PSP-CBS) — also shares a "dopaminergic-adjacent" mechanistic story, but the rationale text itself cautions that PSP-CBS patients typically respond poorly to levodopa (reported response rate <20%), meaning any COMT-inhibitor benefit would likely be marginal. The remaining 8 candidates (PLA2G6-associated neurodegeneration, Rasmussen encephalitis, myelitis, juvenile Hunt-type parkinsonism, transaldolase deficiency, lethal infantile mitochondrial myopathy, fructose-1,6-bisphosphatase deficiency, and a perisylvian polymicrogyria syndrome) each have rationale text explicitly noting weak, indirect, or absent pharmacological linkage to COMT inhibition — these appear to reflect knowledge-graph network propagation rather than genuine drug-disease relationships, and none carry any clinical trial or literature support.

Overview of All 10 TxGNN-Predicted Indications

Rank	Disease	TxGNN Score	Evidence Level	Recommendation
1	PLA2G6-associated neurodegeneration	99.76%	L5	Hold
2	Rasmussen subacute encephalitis	99.73%	L5	Hold
3	Myelitis	99.63%	L5	Hold
4	Paralysis agitans, juvenile, of Hunt	99.60%	L5	Hold
5	Transaldolase deficiency	99.43%	L5	Hold
6	Lethal infantile mitochondrial myopathy	99.28%	L5	Hold
7	Lewy body dementia	99.25%	L4	Research Question
8	Fructose-1,6-bisphosphatase deficiency	99.22%	L5	Hold
9	Polymicrogyria, perisylvian, with cerebellar hypoplasia and arthrogryposis	99.06%	L5	Hold
10	Progressive supranuclear palsy-corticobasal syndrome	99.04%	L4	Research Question

Only ranks 7 and 10 cleared decision stage S1; all others remain at S0 with no clinical trial or literature evidence identified.

Clinical Trial Evidence (Lewy Body Dementia)

Trial Number	Phase	Status	Enrollment	Key Findings
NCT04246437	Phase 1	Recruiting	40	[18F]F-DOPA imaging study in patients with autonomic failure/synucleinopathies (including DLB spectrum). Not an entacapone interventional trial — no treatment arm; provides only dopaminergic-uptake biomarker background (Relevance grade: C).

Note: For Progressive Supranuclear Palsy-Corticobasal Syndrome, one related trial was also found — NCT02994719 (gait pattern analysis, observational, N=120) — but it likewise involves no entacapone intervention (Relevance grade: C).

Literature Evidence (Lewy Body Dementia)

PMID	Year	Type	Journal	Key Findings
23913715	2013	In vitro	Journal of Neuroscience Research	Examined effects of antiparkinsonian agents (including levodopa-pathway drugs) on β-amyloid and α-synuclein oligomer formation in vitro; offers indirect molecular support only.
39259788	2024	In vitro (iPSC organoid model)	Science Advances	Models Lewy body disease using SNCA-triplication cortical organoids to screen therapeutic candidates; mechanistic/disease-model study, not a direct entacapone efficacy study.
11268898	2001	Review	Presse Médicale	General Parkinson's disease review; background context only.

Finland Market Information

Entacapone is currently not marketed in Finland under this evidence pack (0 authorizations on record), so no local product/authorization table can be produced.

Safety Considerations

Please refer to the package insert for safety information. A Blocking-severity data gap (DG001) was identified: TFDA/label warnings and contraindications could not be retrieved for this evidence pack, and the DDI database query returned no results (not_found). This gap must be closed before any formal safety assessment (S1) can proceed for the candidate indications.

Conclusion and Next Steps

Decision: Hold

Rationale:

No completed or ongoing trial directly tests entacapone as a treatment for any of the 10 predicted indications; the only two trials identified (for Lewy body dementia and PSP-CBS) are non-interventional biomarker/observational studies with Grade C relevance.
A Blocking-severity data gap (missing label safety/contraindication data) prevents even a preliminary safety assessment, and the drug is not currently marketed in Finland.

To proceed, the following is needed:

Resolve DG001 (obtain and parse the official package insert for warnings/contraindications) before any S1 safety evaluation.
Resolve DG002 (confirm mechanism of action via DrugBank API) to substantiate the COMT-inhibition rationale formally rather than relying on narrative inference.
If pursuing Lewy body dementia or PSP-CBS further, design or identify an actual interventional study testing entacapone (not just imaging/gait biomarkers) in these populations, with particular attention to the known risk of dopaminergic-agent-induced psychiatric side effects (hallucinations) in LBD patients.
Given the weak/indirect mechanistic rationale for the other 8 candidates, no further investment is recommended for those indications absent new evidence.
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.